Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Newly Approved OTC Eye Drop Could Boost Valeant Turnaround Outlook

Executive Summary

Valeant's Bausch + Lomb subsidiary will have market exclusivity for Lumify, the first OTC brimonidine eye drop. It likely will provide a needed revenue boost as the parent firm navigates a turnaround after incurring more than $30bn debt during the turbulent period under previous management.

Advertisement

Related Content

Valeant Launches Lumify OTC Eye Drops With Vision Of Better Days As Bausch
Valeant Launches Lumify OTC Eye Drops With Vision Of Better Days As Bausch
Valeant Returns $1bn Female Libido Drug For Free
FDA's OTC Naloxone Study Is A Starting Point For Other Switches, Not A Roadmap
Valeant On Track With Debt-Reduction Goals, But Will It Be Enough?
Differin Gel Enters Changed Marketplace Since Last OTC Acne Drug Approval
CDER Talks Switches, Monograph 'More Than Ever,' But Mum On Changes
Bausch + Lomb Buy Vaults Valeant Into Consumer Eye Care Space
Deals Shaping The Medical Industry, March 2013

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS122208

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel